From PVCT .....
Provectus Featured Company in The Life Sciences Report
Friday May 25, 2012
Provectus is a featured company in the current edition of The Life Sciences Report. The report [see below], listing company info and expert analysis, is available at www.thelifesciencesreport.com/pub/co/4394on The Life Sciences Report website.
Provectus Pharmaceuticals Inc. TICKER: PVCT:OTCBB Visit Company Website
Provectus Pharmaceuticals Inc. specializes in developing oncology and dermatology therapies. Its novel oncology drug, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic … read moreside effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The company has received orphan drug designations from the U.S. Food and Drug Administration for its melanoma and hepatocellular carcinoma indications. Its dermatological drug, PH-10, also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed phase 2 trials of PV-10. hide
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Expert Analysis <!-- removed to allow companies to be specified for a quote-->Laura Engel, Stonegate Securities (5/17/12) "Provectus Pharmaceuticals Inc. announced top-line data for its PH-10 randomized, controlled psoriasis study for mild-to-moderate psoriasis: Results clearly showed that the low-dose level was optimal out of three levels tested, with activity similar to what was noted in its earlier single-arm trial and also superior to vehicle. The company is very focused on reaching a licensing agreement with a prospective partner (currently in discussions) to advance the product, which also should provide the company with upfront payments/cash inflow toward further developing of PV-10. . .Provectus appears well positioned."
<!-- removed to allow companies to be specified for a quote-->Yale Jen, ROTH Capital Partners (4/16/12) "Increased awareness of intralesional therapy bodes well for Provectus Pharmaceuticals Inc.'s PV-10 outlook. . .PV-10 appears to exhibit the best overall response rate (37%) among its competitors based on the phase 2 results. . .we are reiterating our Buy rating and $3 price target. The recent approvals of the two new melanoma drugs have not dampened the market potential of PV-10, in our opinion; instead, we believe physicians and key opinion leaders have increasingly identified the proper utilities of different drugs for melanoma treatment. . .with better understanding of the potential value of PV-10."
<!-- removed to allow companies to be specified for a quote-->Yale Jen, ROTH Capital Partners (4/11/12) "We are initiating coverage of Provectus Pharmaceuticals Inc. with a Buy rating. . .the company is nearing an inflection point as it is on the cusp of finalizing discussions with the U.S. Food and Drug Administration for a special protocol assessment designation and ensuing phase 3 pivotal trial for PV-10 in melanoma. . .we view the company's shares as undervalued based on two valuation metrics: Peer comparison analysis and clinical risk-adjusted net present value approach."
<!-- removed to allow companies to be specified for a quote-->Echo He, Maxim Group (3/28/12) "Provectus Pharmaceuticals Inc. has shown supporting evidence for systemic immune response of PV-10 in mice; we reiterate our Buy rating and $3.50 price target. . .and anticipate the company will start phase 3 international trials under a special protocol assessment, possibly in H2/12. In addition, PV-10 has completed phase 1 trials for liver cancer and recurrent breast cancer. This may provide further upside for the stock."
<!-- removed to allow companies to be specified for a quote-->Elemer Piros, Rodman & Renshaw (3/26/12) "Provectus Pharmaceuticals Inc.'s non-clinical data for PV-10 was presented at the Society of Surgical Oncology annual meeting: Data confirmed that PV-10 chemoablation of melanoma lesions induces regression of metastases and PV-10 treatment potentially leads to reduced tumor burden with local immune stimulation against distant lesions. . .we maintain our Market Outperform rating with a $3/share target price for Provectus."
 Corporate Fact Sheet (5/17/12) |
